Shield Therapeutics PLC Director/PDMR Shareholding (5275M)
January 21 2021 - 12:41PM
UK Regulatory
TIDMSTX
RNS Number : 5275M
Shield Therapeutics PLC
21 January 2021
Shield Therapeutics plc
("Shield" or the "Group" or the "Company")
Director/PDMR shareholding
London, UK, 21 January 2021: Shield Therapeutics plc (LSE: STX),
a commercial stage, pharmaceutical company with a focus on
addressing iron deficiency with its lead product Feraccru (R)
/Accrufer (R) (ferric maltol), announces that Hans Peter Hasler,
Non-Executive Chairman, has acquired 100,000 Ordinary Shares in the
Company on 20 January 2021 for consideration of GBP0.59 per
Ordinary Share. Following the transaction, Mr Hasler holds 100,000
shares.
The notification below, which has been made in accordance with
the requirements of the EU Market Abuse Regulation, provides
further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Hans Peter Hasler
------------------------------------------------------- --------------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------------------------------------------
a) Position/status Chairman
------------------------------------------------------- --------------------------------------------------------
b) Initial notification/ Amendment Initial Notification
------------------------------------------------------- --------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
-----------------------------------------------------------------------------------------------------------------
a) Name Shield Therapeutics plc
------------------------------------------------------- --------------------------------------------------------
b) LEI 213800G74QWY15FC3W71
------------------------------------------------------- --------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Ordinary shares of 1.5p each in the capital of the
instrument Company
Identification code ISIN of Ordinary Shares: GB00BYV81293
------------------------------------------------------- --------------------------------------------------------
b) Nature of the transaction Acquisition of Ordinary Shares
------------------------------------------------------- --------------------------------------------------------
c) Price(s) and volume(s) GBP0.59 per Ordinary Share
Volumes: 100,000
------------------------------------------------------- --------------------------------------------------------
d) Aggregated information 100,000
GBP59,000
* Aggregated volume
* Price
------------------------------------------------------- --------------------------------------------------------
e) Date of the transaction 20 January 2021
------------------------------------------------------- --------------------------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
------------------------------------------------------- --------------------------------------------------------
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Tim Watts, CEO +44 (0)20 7186 8500
Nominated Adviser and Joint
Broker
Peel Hunt LLP
James Steel/Dr Christopher
Golden +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/Matt Radley/Alice
Lane +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7584 391
Paul McManus/Lianne Cawthorne 303
About Shield Therapeutics plc
Shield is a de-risked, specialty pharmaceutical company focused
on commercialising its lead product, Feraccru(R)/Accrufer(R), a
novel, non-salt based oral therapy for adults with iron deficiency
with or without anaemia. Feraccru(R)/Accrufer(R) has been approved
for use in the United States, European Union, UK and Switzerland
and has exclusive IP rights until the mid-2030s. Feraccru(R) is
commercialised in the UK and European Union by Norgine B.V. and the
Company is currently in the process of evaluating commercialisation
options for the US market, including the potential launch of
Accrufer (R) in the US by Shield. Shield also has an exclusive
licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd.,
for the development and commercialisation of
Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com .
Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDFLFLFFLXBBD
(END) Dow Jones Newswires
January 21, 2021 12:41 ET (17:41 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jul 2023 to Jul 2024
